Abby Marquez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abby Marquez has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Elena S. Koltun
Revolution Medicines, Inc., Redwood City, California
95 shared publications - Jacqueline A. M. Smith
Revolution Medicines, Redwood City, USA
95 shared publications - Kyle J. Seamon
Revolution Medicines, Inc., Redwood City, California
95 shared publications - Adrian L. Gill
Revolution Medicines, Inc., Redwood City, California
94 shared publications - Aidan C.A. Tomlinson
Revolution Medicines, Inc., Redwood City, California
94 shared publications - David Wildes
Revolution Medicines, Inc., Redwood City, California
94 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Structural and biochemical properties of mutant KRAS proteins. A, Overlaid crystal structures of wild-type (WT) KRAS (green) and KRASG13C (light blue). B, Ramachandran analysis of the dihedral angles of the codon 12 residues (open symbols) and the codon 13 residues (filled symbols) from the crystal structures of WT (circle) and G13C-mutant (square) crystal structures. The energetically favorable regions for generic amino acids (shaded blue) and glycine (shaded pink) are shown (31). C, Depiction of the phi and psi angles for codon 13 by Newman projection as obtained from the WT and G13C-mutant crystal structures. D, The fraction of KRAS-mutant protein remaining folded as assessed by pulse proteolysis for varying concentrations of urea (representative of n = 3). E, The ΔΔGunfolding for each mutant relative to WT KRAS calculated from the concentration of urea resulting in half-maximal unfolding of the KRAS-mutant proteins (Cm) from D. F, The first-order rate constant for the exchange of mantGDP for the GTP-analog GMPPNP for KRAS-mutant proteins at 37°C. G, The first-order rate constant for the hydrolysis of GTP to GDP for KRAS-mutant proteins at 37°C.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Structural and biochemical properties of mutant KRAS proteins. A, Overlaid crystal structures of wild-type (WT) KRAS (green) and KRASG13C (light blue). B, Ramachandran analysis of the dihedral angles of the codon 12 residues (open symbols) and the codon 13 residues (filled symbols) from the crystal structures of WT (circle) and G13C-mutant (square) crystal structures. The energetically favorable regions for generic amino acids (shaded blue) and glycine (shaded pink) are shown (31). C, Depiction of the phi and psi angles for codon 13 by Newman projection as obtained from the WT and G13C-mutant crystal structures. D, The fraction of KRAS-mutant protein remaining folded as assessed by pulse proteolysis for varying concentrations of urea (representative of n = 3). E, The ΔΔGunfolding for each mutant relative to WT KRAS calculated from the concentration of urea resulting in half-maximal unfolding of the KRAS-mutant proteins (Cm) from D. F, The first-order rate constant for the exchange of mantGDP for the GTP-analog GMPPNP for KRAS-mutant proteins at 37°C. G, The first-order rate constant for the hydrolysis of GTP to GDP for KRAS-mutant proteins at 37°C.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
RMC-8839 has activity against KRASG13C tumor xenografts. A, Mice bearing NCI-H1734 CDX tumors were treated with a single oral dose of RMC-8839, and the plasma concentrations of RMC-8839 were monitored (mean ± SEM, n = 3). B, NCI-H1734 tumors excised at various times after a single 100 mg/kg dose of RMC-8839 were subjected to LC/MS to quantify the covalent modification of KRASG13C and the expression of DUSP6 mRNA (mean ± SEM, n = 3). Mice bearing (C) NCI-H1734 CDX tumors (n = 10 per group) or (D) ST2822B PDX tumors (n = 5 per group) were orally administered RMC-8839 daily, and the tumor volume was assessed for 28 days (mean ± SEM). WT, wild type. (C-D) **, P < 0.01; ***, P < 0.001 two-way repeated measures ANOVA compared to the control on the last treatment day of the control group.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
RMC-8839 has activity against KRASG13C tumor xenografts. A, Mice bearing NCI-H1734 CDX tumors were treated with a single oral dose of RMC-8839, and the plasma concentrations of RMC-8839 were monitored (mean ± SEM, n = 3). B, NCI-H1734 tumors excised at various times after a single 100 mg/kg dose of RMC-8839 were subjected to LC/MS to quantify the covalent modification of KRASG13C and the expression of DUSP6 mRNA (mean ± SEM, n = 3). Mice bearing (C) NCI-H1734 CDX tumors (n = 10 per group) or (D) ST2822B PDX tumors (n = 5 per group) were orally administered RMC-8839 daily, and the tumor volume was assessed for 28 days (mean ± SEM). WT, wild type. (C-D) **, P < 0.01; ***, P < 0.001 two-way repeated measures ANOVA compared to the control on the last treatment day of the control group.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
MAPK signaling is driven by mutant and wild-type (WT) RAS isoforms in KRASG13C-mutant cancer cell lines. A, KRASG13C-mutant lung adenocarcinoma (NCI-H1734, NCI-H1355, MOR, MOR/CPR), clear-cell ovarian cancer (TOV-21G), or cholangiocarcinoma (KKU-213) cell lines were treated with the indicated concentrations of RMC-8839 or RMC-7977 for 4 hours, then lysed and subjected to immunoblotting with the indicated antibodies. B, NCI-H1355 or TOV-21G cell lines were modified with CRISPR to knock out all WT RAS isoforms (NRAS, HRAS, and WT KRAS). These engineered cell lines were treated with RMC-8839 for 4 hours, then lysed and subjected to immunoblotting with the indicated antibodies. The separate bands corresponding to NRAS/HRAS, KRAS, and covalently modified KRAS are indicated on RAS blots.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
MAPK signaling is driven by mutant and wild-type (WT) RAS isoforms in KRASG13C-mutant cancer cell lines. A, KRASG13C-mutant lung adenocarcinoma (NCI-H1734, NCI-H1355, MOR, MOR/CPR), clear-cell ovarian cancer (TOV-21G), or cholangiocarcinoma (KKU-213) cell lines were treated with the indicated concentrations of RMC-8839 or RMC-7977 for 4 hours, then lysed and subjected to immunoblotting with the indicated antibodies. B, NCI-H1355 or TOV-21G cell lines were modified with CRISPR to knock out all WT RAS isoforms (NRAS, HRAS, and WT KRAS). These engineered cell lines were treated with RMC-8839 for 4 hours, then lysed and subjected to immunoblotting with the indicated antibodies. The separate bands corresponding to NRAS/HRAS, KRAS, and covalently modified KRAS are indicated on RAS blots.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
KRASG13X has reduced oncopotency. The concentration of GAP required to convert half of the RAS(ON) to RAS(OFF) (EC50) is plotted for NF1 (A) and RASA1 (B) across wild-type (WT) and mutant KRAS proteins. The highest concentration tested was 10−5 mol/L, so it is the upper limit. C, Cellular levels of RAS(ON) assessed through a RAS-RAF nanoBRET signal upon cotransfection of varying ratios of NF1 GAP domain and KRAS plasmids. D, Comutations in patients with KRASG12C NSCLC vs. KRASG13C NSCLC, KRASG12D vs. KRASG13D NSCLC, KRASG12X vs. KRASG13X NSCLC, or KRASG12D vs. KRASG13D colorectal cancer compared by log2(odds ratio) and FDR from a χ2 test followed by the Benjamini–Hochberg procedure. Lines indicate log2(odds ratio) < −1 or >1 and P value < 0.05 (see “Methods”). E, Parental or engineered MIA PaCa-2 cells containing the indicated KRAS mutation in combination with NF1 knockout or BRAFD594G expression were monitored for growth in spheroid culture. F, Parental MIA PaCa-2 (KRASG12C) or engineered KRASG13C-mutant MIA PaCa-2 cells were implanted subcutaneously in NOD-SCID mice, and tumor size was assessed (n = 5 per group). G, Engineered KRASG13C-mutant MIA PaCa-2 cells and two clonal cell lines with NF1 knockout were implanted subcutaneously in NOD-SCID mice, and tumor size was measured (n = 6 per group). F-G *, P < 0.05; **, P < 0.01; ***, P < 0.001 two way repeated measures ANOVA compared to the control on the last treatment day of the control group.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
KRASG13X has reduced oncopotency. The concentration of GAP required to convert half of the RAS(ON) to RAS(OFF) (EC50) is plotted for NF1 (A) and RASA1 (B) across wild-type (WT) and mutant KRAS proteins. The highest concentration tested was 10−5 mol/L, so it is the upper limit. C, Cellular levels of RAS(ON) assessed through a RAS-RAF nanoBRET signal upon cotransfection of varying ratios of NF1 GAP domain and KRAS plasmids. D, Comutations in patients with KRASG12C NSCLC vs. KRASG13C NSCLC, KRASG12D vs. KRASG13D NSCLC, KRASG12X vs. KRASG13X NSCLC, or KRASG12D vs. KRASG13D colorectal cancer compared by log2(odds ratio) and FDR from a χ2 test followed by the Benjamini–Hochberg procedure. Lines indicate log2(odds ratio) < −1 or >1 and P value < 0.05 (see “Methods”). E, Parental or engineered MIA PaCa-2 cells containing the indicated KRAS mutation in combination with NF1 knockout or BRAFD594G expression were monitored for growth in spheroid culture. F, Parental MIA PaCa-2 (KRASG12C) or engineered KRASG13C-mutant MIA PaCa-2 cells were implanted subcutaneously in NOD-SCID mice, and tumor size was assessed (n = 5 per group). G, Engineered KRASG13C-mutant MIA PaCa-2 cells and two clonal cell lines with NF1 knockout were implanted subcutaneously in NOD-SCID mice, and tumor size was measured (n = 6 per group). F-G *, P < 0.05; **, P < 0.01; ***, P < 0.001 two way repeated measures ANOVA compared to the control on the last treatment day of the control group.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Development of the covalent RAS(ON) G13C-selective inhibitor RMC-8839. A, Chemical structures of Cmpd-1 as previously published (27) and Cmpd-3, designed to target KRASG13C. B, Overlay of CYPA–compound–KRAS tricomplex crystal structures shows covalent bond formation between Cmpd-1 and KRASG12C but not between Cmpd-1 and KRASG13C. C, Time-dependent covalent modification of KRASG13C (1 μmol/L) in the presence of compounds (10 μmol/L) and CYPA (25 μmol/L) as assessed by mass spectrometry. D, Cmpd-2 tricomplex crystal structure reveals that the spirocyclic linker of Cmpd-2 achieves efficient covalent modification by projecting around KRASY32 to place the acrylamide warhead near G13C. E, Chemical structure of RMC-8839. F, Time-dependent covalent modification of KRASG13C (0.5 nmol/L) in the presence of varying concentrations of RMC-8839 and excess CYPA (25 μmol/L) as assessed by gel electrophoresis mobility shift. G, The kinetics of cellular KRASG13C–RAF(RBD) complex disruption were assessed by nanoBRET at varying concentrations of RMC-8839. H, The observed rate of biochemical KRASG13C covalent modification or cellular KRASG13C–RAF(RBD) complex disruption is depicted for varying concentrations of RMC-8839. The selectivity of RMC-8839 was assessed using (I) KRASG13C-RAF(RBD) or KRASWT-RAF(RBD) cellular nanoBRET assay after 4 hours of treatment. J, NCI-H1734 or NCI-H1975 intracellular pERK to total ERK levels after 4 hours of treatment and (K) NCI-H1734 or NCI-H1975 cellular proliferation assays after 5 days of treatment. L, The potency (EC50) of RMC-8839 for KRASG13C-mutant or KRASWT across the cellular RAS-RAF nanoBRET, pERK, and proliferation assays shown in I–K, respectively. WT, wild type.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Development of the covalent RAS(ON) G13C-selective inhibitor RMC-8839. A, Chemical structures of Cmpd-1 as previously published (27) and Cmpd-3, designed to target KRASG13C. B, Overlay of CYPA–compound–KRAS tricomplex crystal structures shows covalent bond formation between Cmpd-1 and KRASG12C but not between Cmpd-1 and KRASG13C. C, Time-dependent covalent modification of KRASG13C (1 μmol/L) in the presence of compounds (10 μmol/L) and CYPA (25 μmol/L) as assessed by mass spectrometry. D, Cmpd-2 tricomplex crystal structure reveals that the spirocyclic linker of Cmpd-2 achieves efficient covalent modification by projecting around KRASY32 to place the acrylamide warhead near G13C. E, Chemical structure of RMC-8839. F, Time-dependent covalent modification of KRASG13C (0.5 nmol/L) in the presence of varying concentrations of RMC-8839 and excess CYPA (25 μmol/L) as assessed by gel electrophoresis mobility shift. G, The kinetics of cellular KRASG13C–RAF(RBD) complex disruption were assessed by nanoBRET at varying concentrations of RMC-8839. H, The observed rate of biochemical KRASG13C covalent modification or cellular KRASG13C–RAF(RBD) complex disruption is depicted for varying concentrations of RMC-8839. The selectivity of RMC-8839 was assessed using (I) KRASG13C-RAF(RBD) or KRASWT-RAF(RBD) cellular nanoBRET assay after 4 hours of treatment. J, NCI-H1734 or NCI-H1975 intracellular pERK to total ERK levels after 4 hours of treatment and (K) NCI-H1734 or NCI-H1975 cellular proliferation assays after 5 days of treatment. L, The potency (EC50) of RMC-8839 for KRASG13C-mutant or KRASWT across the cellular RAS-RAF nanoBRET, pERK, and proliferation assays shown in I–K, respectively. WT, wild type.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
RMC-8839 and multiselective RAS(ON) inhibitor combinations increase the depth and durability of tumor regressions. KRASG13C-mutant cancer cell lines were treated with a matrix of RMC-8839 and RMC-7977 combinations, and (A) pERK levels relative to total ERK levels were assessed after 4 hours of treatment, or (B) cell viability was assessed after 5 days of treatment. Mice bearing NCI-H1734 CDX tumors were treated with a single dose of either a single agent or the combination and (C) tumor levels of pERK or cleaved caspase 3 were assessed by IHC. D, Mice bearing NCI-H1734 CDX tumors were treated daily as indicated, and tumor volume was measured for 28 days (n = 9 per group, mean ± SEM), or ST2822B PDX tumors were treated daily with the indicated single-agent or combination treatment, and tumor volume was measured for 86 days (n = 3 per group, mean ± SEM). *, P < 0.05; ***, P < 0.001 two-way repeated measures ANOVA compared to the control on the last treatment day of the control group.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
RMC-8839 and multiselective RAS(ON) inhibitor combinations increase the depth and durability of tumor regressions. KRASG13C-mutant cancer cell lines were treated with a matrix of RMC-8839 and RMC-7977 combinations, and (A) pERK levels relative to total ERK levels were assessed after 4 hours of treatment, or (B) cell viability was assessed after 5 days of treatment. Mice bearing NCI-H1734 CDX tumors were treated with a single dose of either a single agent or the combination and (C) tumor levels of pERK or cleaved caspase 3 were assessed by IHC. D, Mice bearing NCI-H1734 CDX tumors were treated daily as indicated, and tumor volume was measured for 28 days (n = 9 per group, mean ± SEM), or ST2822B PDX tumors were treated daily with the indicated single-agent or combination treatment, and tumor volume was measured for 86 days (n = 3 per group, mean ± SEM). *, P < 0.05; ***, P < 0.001 two-way repeated measures ANOVA compared to the control on the last treatment day of the control group.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Complete covalent modification of KRAS G13C by RMC-8839 in the partially responsive cell lines H1355 and TOV-21G. The covalent modification of KRAS G13C was monitored by disappearance of the unmodified KRAS G13C peptide as assessed by protein digestion and mass spectrometry ([RMC-8839] = 100 nM, 4 hrs)
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Complete covalent modification of KRAS G13C by RMC-8839 in the partially responsive cell lines H1355 and TOV-21G. The covalent modification of KRAS G13C was monitored by disappearance of the unmodified KRAS G13C peptide as assessed by protein digestion and mass spectrometry ([RMC-8839] = 100 nM, 4 hrs)
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Half-Lives of KRAS G13C and KRAS G12C in cancer cell lines by SILAC. (A) NCI-H1355 or (B) NCI-H358 cells were cultured in Heavy RPMI 1640 for SILAC for more than 5 doublings to ensure complete heavy isotope incorporation. Cells were then re-plated in light RPMI and cells were harvested at after various time points. The relative isotope abundance of the indicated mutant-specific or total KRAS peptide [(Total Area of Heavy Peptide)/(Total Area of Heavy Peptide + Total Area of Light Peptide)] was plotted for each sample.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Half-Lives of KRAS G13C and KRAS G12C in cancer cell lines by SILAC. (A) NCI-H1355 or (B) NCI-H358 cells were cultured in Heavy RPMI 1640 for SILAC for more than 5 doublings to ensure complete heavy isotope incorporation. Cells were then re-plated in light RPMI and cells were harvested at after various time points. The relative isotope abundance of the indicated mutant-specific or total KRAS peptide [(Total Area of Heavy Peptide)/(Total Area of Heavy Peptide + Total Area of Light Peptide)] was plotted for each sample.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
RMC-8839 effects on cellular signaling in KRAS G13C cell lines at later time points. The indicated cell lines were treated with RMC-8839 for 24 hours prior to lysis and evaluation of protein levels by immuno-blotting.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
RMC-8839 effects on cellular signaling in KRAS G13C cell lines at later time points. The indicated cell lines were treated with RMC-8839 for 24 hours prior to lysis and evaluation of protein levels by immuno-blotting.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Basal Phospho-RTK Profiling of KRAS G13C-Mutant Cell Lines. KRAS G13C-mutant cell lines (NCI-H1355, KKU-213, TOV-21G, NCI-H1734, MOR, and MOR/CPR) or an EGFR-mutant control cell line (NCI-H1975) were lysed and subjected to membrane array (Proteome Profiler Human Phospho-RTK Array). Duplicate spots with detectable signals are indicated with the boxes.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Basal Phospho-RTK Profiling of KRAS G13C-Mutant Cell Lines. KRAS G13C-mutant cell lines (NCI-H1355, KKU-213, TOV-21G, NCI-H1734, MOR, and MOR/CPR) or an EGFR-mutant control cell line (NCI-H1975) were lysed and subjected to membrane array (Proteome Profiler Human Phospho-RTK Array). Duplicate spots with detectable signals are indicated with the boxes.